{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:22:17Z","timestamp":1778916137705,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-67570-0","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:01:55Z","timestamp":1721793715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals"],"prefix":"10.1038","volume":"14","author":[{"given":"Anna","family":"Offersgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos R.","family":"Duarte Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Anbro","family":"Gammeltoft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrine T.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Marichal-Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garazi Pe\u00f1a","family":"Alzua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"S\u00f8lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper Hansen","family":"Bonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel K.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Elvang","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenn","family":"Holmbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith Margarete","family":"Gottwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"67570_CR1","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology immune escape transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"67570_CR2","unstructured":"WHO. Initial Risk Evaluation of BA.2.86 and its sublineages, 21 November 2023. Accessed 2023 Dec 21. WHO. Available from: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/21112023_ba.2.86_ire.pdf?sfvrsn=8876def1_3 (2023)."},{"key":"67570_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527 (2020).","journal-title":"Nature"},{"key":"67570_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875\u2013884 (2021).","journal-title":"N. Engl. J. Med."},{"key":"67570_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1126\/science.370.6522.1263","volume":"370","author":"J Cohen","year":"2020","unstructured":"Cohen, J. China\u2019s vaccine gambit. Science 370, 1263\u20131267 (2020).","journal-title":"Science"},{"key":"67570_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/vaccines9091033","volume":"9","author":"MN Uddin","year":"2021","unstructured":"Uddin, M. N. & Roni, M. A. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines (Basel) 9, 1033 (2021).","journal-title":"Vaccines (Basel)"},{"key":"67570_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","volume":"598","author":"S Mallapaty","year":"2021","unstructured":"Mallapaty, S. China\u2019s COVID vaccines have been crucial\u2014now immunity is waning. Nature 598, 398\u2013399 (2021).","journal-title":"Nature"},{"key":"67570_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA 326, 35\u201345 (2021).","journal-title":"JAMA"},{"key":"67570_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1473-3099(21)00674-5","volume":"22","author":"D Desai","year":"2022","unstructured":"Desai, D. et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: A test-negative, case-control study. Lancet Infect. Dis. 22, 349\u2013356 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"67570_CR10","doi-asserted-by":"publisher","first-page":"2149935","DOI":"10.1080\/22221751.2022.2149935","volume":"12","author":"H Xu","year":"2023","unstructured":"Xu, H. et al. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: Real-world study in Jilin Province China. Emerg. Microbes Infect. 12, 2149935 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"67570_CR11","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1080\/22221751.2022.2114854","volume":"11","author":"VKC Yan","year":"2022","unstructured":"Yan, V. K. C. et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: A case-control study. Emerg. Microbes Infect. 11, 2304\u20132314 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"67570_CR12","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1016\/j.vaccine.2023.10.036","volume":"41","author":"H Yang","year":"2023","unstructured":"Yang, H. et al. Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing. Vaccine 41, 7201\u20137205 (2023).","journal-title":"Vaccine"},{"key":"67570_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12931-023-02542-y","volume":"24","author":"T Zeng","year":"2023","unstructured":"Zeng, T. et al. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: A matched cohort study of adult close contacts. Respir. Res. 24, 246 (2023).","journal-title":"Respir. Res."},{"key":"67570_CR14","unstructured":"WHO. Statement on the antigen composition of COVID-19 vaccines. Accessed 2023 Dec 6. Available from: https:\/\/www.who.int\/news\/item\/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines (2023)."},{"key":"67570_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00097-21","volume":"65","author":"S Ramirez","year":"2021","unstructured":"Ramirez, S. et al. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication. Antimicrob. Agents Chemother. 65, e0009721 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"67570_CR16","doi-asserted-by":"publisher","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","volume":"22","author":"Y Shu","year":"2017","unstructured":"Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 22, 30494 (2017).","journal-title":"Euro Surveill."},{"key":"67570_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/vaccines9070706","volume":"9","author":"A Offersgaard","year":"2021","unstructured":"Offersgaard, A. et al. SARS-CoV-2 production in a scalable high cell density bioreactor. Vaccines (Basel) 9, 706 (2021).","journal-title":"Vaccines (Basel)"},{"key":"67570_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/vaccines10010075","volume":"10","author":"C Solund","year":"2022","unstructured":"Solund, C. et al. Analysis of neutralization titers against SARS-CoV-2 in health-care workers vaccinated with prime-boost mRNA-mRNA or vector-mRNA COVID-19 vaccines. Vaccines (Basel) 10, 75 (2022).","journal-title":"Vaccines (Basel)"},{"key":"67570_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104475","volume":"89","author":"AP Underwood","year":"2023","unstructured":"Underwood, A. P. et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and\/or COVID-19 vaccination. EBioMedicine 89, 104475 (2023).","journal-title":"EBioMedicine"},{"key":"67570_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).","journal-title":"Cell Rep."},{"key":"67570_CR21","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.1126\/sciadv.add7197","volume":"8","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci. Adv. 8, 7197 (2022).","journal-title":"Sci. Adv."},{"key":"67570_CR22","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.isci.2023.105949","volume":"26","author":"A Offersgaard","year":"2023","unstructured":"Offersgaard, A. et al. An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience 26, 105949 (2023).","journal-title":"iScience"},{"key":"67570_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.abn8939","volume":"377","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science 377, 428\u2013433 (2022).","journal-title":"Science"},{"key":"67570_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s42003-023-04923-x","volume":"6","author":"SB Park","year":"2023","unstructured":"Park, S. B. et al. SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype. Commun. Biol. 6, 556 (2023).","journal-title":"Commun. Biol."},{"key":"67570_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.virs.2022.01.029","volume":"37","author":"ST Sonnleitner","year":"2022","unstructured":"Sonnleitner, S. T. et al. The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro. Virol. Sin. 37, 198\u2013207 (2022).","journal-title":"Virol. Sin."},{"key":"67570_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/hep.32772","volume":"77","author":"GP Alzua","year":"2023","unstructured":"Alzua, G. P. et al. Identification of novel neutralizing determinants for protection against HCV. Hepatology 77, 982\u2013996 (2023).","journal-title":"Hepatology"},{"key":"67570_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001006","volume":"19","author":"MO Pohl","year":"2021","unstructured":"Pohl, M. O. et al. SARS-CoV-2 variants reveal features critical for replication in primary human cells. PLoS Biol. 19, e3001006 (2021).","journal-title":"PLoS Biol."},{"key":"67570_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/v15010013","volume":"15","author":"G Mathez","year":"2022","unstructured":"Mathez, G., Pillonel, T., Bertelli, C. & Cagno, V. Alpha and Omicron SARS-CoV-2 adaptation in an upper respiratory tract model. Viruses 15, 13 (2022).","journal-title":"Viruses"},{"key":"67570_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00705-021-05343-0","volume":"167","author":"Y Kim","year":"2022","unstructured":"Kim, Y. et al. Trypsin enhances SARS-CoV-2 infection by facilitating viral entry. Arch. Virol. 167, 441\u2013458 (2022).","journal-title":"Arch. Virol."},{"key":"67570_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2143283","volume":"12","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice. Emerg. Microbes Infect. 12, e2143283 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"67570_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41541-023-00776-x","volume":"8","author":"CP Ong","year":"2023","unstructured":"Ong, C. P. et al. Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants. NPJ Vaccines 8, 177 (2023).","journal-title":"NPJ Vaccines"},{"key":"67570_CR32","doi-asserted-by":"publisher","first-page":"19176","DOI":"10.1038\/s41598-023-46025-y","volume":"13","author":"N Patel","year":"2023","unstructured":"Patel, N. et al. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. Sci. Rep. 13, 19176 (2023).","journal-title":"Sci. Rep."},{"key":"67570_CR33","doi-asserted-by":"publisher","first-page":"2281733","DOI":"10.1080\/21645515.2023.2281733","volume":"19","author":"VM Andrade","year":"2023","unstructured":"Andrade, V. M. et al. Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models. Hum. Vaccin. Immunother. 19, 2281733 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"67570_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"67570_CR35","doi-asserted-by":"publisher","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","volume":"24","author":"B Ganneru","year":"2021","unstructured":"Ganneru, B. et al. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience 24, 102298 (2021).","journal-title":"iScience"},{"key":"67570_CR36","doi-asserted-by":"publisher","first-page":"0120623","DOI":"10.1128\/jvi.01206-23","volume":"98","author":"TL Bricker","year":"2024","unstructured":"Bricker, T. L. et al. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters. J. Virol. 98, 0120623 (2024).","journal-title":"J. Virol."},{"key":"67570_CR37","doi-asserted-by":"crossref","unstructured":"Boon, J., Soudani, N., Bricker, T., Darling, T., Seehra, K., Patel, N., et al. Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters. Preprint at Research Square: https:\/\/www.researchsquare.com\/article\/rs-3873514\/v1. (2024).","DOI":"10.21203\/rs.3.rs-3873514\/v1"},{"key":"67570_CR38","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.isci.2021.102054","volume":"24","author":"S Mohandas","year":"2021","unstructured":"Mohandas, S. et al. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model. iScience 24, 102054 (2021).","journal-title":"iScience"},{"key":"67570_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","volume":"29","author":"SM Scheaffer","year":"2023","unstructured":"Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med. 29, 247\u2013257 (2023).","journal-title":"Nat. Med."},{"key":"67570_CR40","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.7150\/ijbs.72109","volume":"18","author":"ZW Ye","year":"2022","unstructured":"Ye, Z. W. et al. Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. Int. J. Biol. Sci. 18, 4781\u20134791 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"67570_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","volume":"607","author":"RK Suryawanshi","year":"2022","unstructured":"Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature 607, 351\u2013355 (2022).","journal-title":"Nature"},{"key":"67570_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/v14050991","volume":"14","author":"M Golawski","year":"2022","unstructured":"Golawski, M., Lewandowski, P., Jablonska, I. & Delijewski, M. The reassessed potential of SARS-CoV-2 attenuation for COVID-19 vaccine development-a systematic review. Viruses 14, 991 (2022).","journal-title":"Viruses"},{"key":"67570_CR43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2213907","volume":"388","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Antibody response to Omicron BA.4-BA.5 bivalent booster. N. Engl. J. Med. 388, 567\u2013569 (2023).","journal-title":"N. Engl. J. Med."},{"key":"67570_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156 (2024).","journal-title":"Nature"},{"key":"67570_CR45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/vaccines10071149","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Vaccination with Omicron inactivated vaccine in pre-vaccinated mice protects against SARS-CoV-2 prototype and Omicron variants. Vaccines (Basel) 10, 1149 (2022).","journal-title":"Vaccines (Basel)"},{"key":"67570_CR46","doi-asserted-by":"publisher","first-page":"1241153","DOI":"10.3389\/fimmu.2023.1241153","volume":"14","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: A randomized, double-blind, active-controlled Phase III clinical trial. Front. Immunol. 14, 1241153 (2023).","journal-title":"Front. Immunol."},{"key":"67570_CR47","unstructured":"Chalkias, S., McGhee, N., Whatley, J.L., Essink, B., Brosz, A., Tomassini, J.E., et al. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines. J. Infect. Dis. Online ahead of print (2024)."},{"key":"67570_CR48","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S1473-3099(23)00690-4","volume":"24","author":"MV Stankov","year":"2024","unstructured":"Stankov, M. V. et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect. Dis. 24, e1\u2013e3 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"67570_CR49","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","volume":"30","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 30, 880-886.e4 (2022).","journal-title":"Cell Host Microbe."},{"key":"67570_CR50","doi-asserted-by":"publisher","first-page":"199255","DOI":"10.1016\/j.virusres.2023.199255","volume":"339","author":"M Essaidi-Laziosi","year":"2024","unstructured":"Essaidi-Laziosi, M. et al. Distinct phenotype of SARS-CoV-2 Omicron BA.1 in human primary cells but no increased host range in cell lines of putative mammalian reservoir species. Virus Res. 339, 199255 (2024).","journal-title":"Virus Res."},{"key":"67570_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02186-21","volume":"96","author":"MZ Chaudhry","year":"2022","unstructured":"Chaudhry, M. Z. et al. Rapid SARS-CoV-2 adaptation to available cellular proteases. J. Virol. 96, e0218621 (2022).","journal-title":"J. Virol."},{"key":"67570_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02680-20","volume":"65","author":"KA Gammeltoft","year":"2021","unstructured":"Gammeltoft, K. A. et al. Hepatitis C virus protease inhibitors show differential efficacy and interactions with Remdesivir for treatment of SARS-CoV-2 in vitro. Antimicrob. Agents Chemother. 65, e0268020 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"67570_CR53","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/v14020172","volume":"14","author":"U Fahn\u00f8e","year":"2022","unstructured":"Fahn\u00f8e, U. et al. Versatile SARS-CoV-2 reverse-genetics systems for the study of antiviral resistance and replication. Viruses 14, 172 (2022).","journal-title":"Viruses"},{"key":"67570_CR54","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/v15091970","volume":"15","author":"KA Gammeltoft","year":"2023","unstructured":"Gammeltoft, K. A. et al. Substitutions in SARS-CoV-2 Mpro selected by protease inhibitor boceprevir confer resistance to Nirmatrelvir. Viruses 15, 1970 (2023).","journal-title":"Viruses"},{"key":"67570_CR55","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/vaccines10020249","volume":"10","author":"A Offersgaard","year":"2022","unstructured":"Offersgaard, A. et al. High-Titer Hepatitis C virus production in a scalable single-use high cell density bioreactor. Vaccines (Basel) 10, 249 (2022).","journal-title":"Vaccines (Basel)"},{"key":"67570_CR56","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1089\/hum.2019.284","volume":"32","author":"P Marichal-Gallardo","year":"2021","unstructured":"Marichal-Gallardo, P. et al. Single-use capture purification of adeno-associated viral gene transfer vectors by membrane-based steric exclusion chromatography. Hum. Gene Ther. 32, 959\u2013974 (2021).","journal-title":"Hum. Gene Ther."},{"key":"67570_CR57","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.3390\/v13102082","volume":"13","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. Viruses 13, 2082 (2021).","journal-title":"Viruses"},{"key":"67570_CR58","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/gutjnl-2021-326323","volume":"72","author":"GP Alzua","year":"2023","unstructured":"Alzua, G. P. et al. Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice. Gut 72, 560\u2013572 (2023).","journal-title":"Gut"},{"key":"67570_CR59","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/0300985812469638","volume":"50","author":"AB Grossi","year":"2013","unstructured":"Grossi, A. B., Leifsson, P. S., Jensen, H. E., Vainer, B. & Iburg, T. Histologic and immunohistochemical classification of 41 bovine adrenal gland neoplasms. Vet. Pathol. 50, 534\u2013542 (2013).","journal-title":"Vet. Pathol."},{"key":"67570_CR60","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67570-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:03:43Z","timestamp":1721797423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67570-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67570"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67570-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17039"}}